Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
There is a new form of cancer treatment called immunotherapy which does not attack cancer
directly but works on the immune system to make it more effective. This type of treatment may
have side effects which are called autoimmune side effects and are caused by the immune
system attacking the normal parts of the body. At the moment doctors cannot predict which
patients may be at more risk of developing such autoimmune side effects and doctors also
cannot predict which patients are more likely to benefit. This study will analyse blood
samples from patients receiving immunotherapy to see if markers can be identified to help
make such predictions.
Details
Lead Sponsor:
Royal Free Hospital NHS Foundation Trust
Collaborators:
Merck Sharp & Dohme Corp. University College, London